{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:29:04Z","timestamp":1785382144874,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pseudomyxoma peritonei (PMP) is a rare malignancy, and there is insufficient evidence about systemic chemotherapy for this disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated the efficacy and safety of a chemotherapeutic regimen with 5-fluorouracil and oxaliplatin (modified FOLFOX6, mFOLFOX6) for patients with unresectable pseudomyxoma peritonei. Patients who received the therapy between April 2000 and February 2019 at the Department of Medical Oncology, Tohoku University Hospital, were enrolled in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight patients were treated with mFOLFOX6. The sites of primary tumor were appendix in six patients, ovary in a patient, and urachus in a patient. Six patients received surgery. Seven patients had histologically high-grade PMP, and one patient had low-grade PMP. The median follow-up duration was 27.2\u00a0months. All the patients had non-measurable regions as the targets of tumor response. Non-complete response or non-progressive disease was observed in seven patients, with a disease control rate of 87.5%. The median progression-free survival and overall survival were 13.0\u00a0months and 27.9\u00a0months, respectively. An obvious reduction in the symptoms was observed in two patients. Five patients experienced decline in the serum tumor markers, CEA or CA19-9. The grade 3\/4 toxicity that was observed was grade 4 neutropenia in one patient and grade 3 neutropenia in two patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>mFOLFOX6 might be an effective and tolerable treatment option for patients with unresectable PMP. To our knowledge, this is the first case series of mFOLFOX6 in patients with unresectable PMP and the first case series of systemic chemotherapy for Asian patients with unresectable PMP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10147-019-01592-x","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T12:04:28Z","timestamp":1575979468000},"page":"774-781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei"],"prefix":"10.1007","volume":"25","author":[{"given":"Sakura","family":"Hiraide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"1592_CR1","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","volume":"19","author":"BMZC Ronnett","year":"1995","unstructured":"Ronnett BM, Zahr CM, Kurman RJ et al (1995) Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d. Am J Surg Pathol 19:1390\u20131408","journal-title":"Am J Surg Pathol"},{"key":"1592_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","volume":"30","author":"RF Bradley","year":"2006","unstructured":"Bradley RF, Stewart JH 4th, Russell GB et al (2006) Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 30:551\u2013559","journal-title":"Am J Surg Pathol"},{"key":"1592_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/00000658-199402000-00002","volume":"219","author":"DB Gough","year":"1994","unstructured":"Gough DB, Donohue JH, Schutt AJ et al (1994) Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 219:112\u2013119","journal-title":"Ann Surg"},{"key":"1592_CR4","unstructured":"Bosman FT, Carneiro F, Hruban RH et al (eds) (2010) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on Cancer, Lyon, France"},{"key":"1592_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","volume":"34","author":"RM Smeenk","year":"2008","unstructured":"Smeenk RM, van Velthuysen ML, Verwaal VJ et al (2008) Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 34:196\u2013201","journal-title":"Eur J Surg Oncol"},{"key":"1592_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69\u201376","journal-title":"Lancet Oncol"},{"key":"1592_CR7","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","volume":"30","author":"TC Chua","year":"2012","unstructured":"Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449\u20132456","journal-title":"J Clin Oncol"},{"key":"1592_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/bjs.10716","volume":"105","author":"JB Delhorme","year":"2018","unstructured":"Delhorme JB, Severac F, Averous G et al (2018) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg 105:668\u2013676","journal-title":"Br J Surg"},{"key":"1592_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/sj.bjc.6604522","volume":"99","author":"AL Farquharson","year":"2008","unstructured":"Farquharson AL, Pranesh N, Witham G et al (2008) A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer 99:591\u2013596","journal-title":"Br J Cancer"},{"key":"1592_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1634\/theoncologist.2014-0106","volume":"19","author":"F Pietrantonio","year":"2014","unstructured":"Pietrantonio F, Maggi C, Fanetti G et al (2014) FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 19:845\u2013850","journal-title":"Oncologist"},{"key":"1592_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","volume":"14","author":"F Pietrantonio","year":"2016","unstructured":"Pietrantonio F, Berenato R, Maggi C et al (2016) GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. J Transl Med 14:125","journal-title":"J Transl Med"},{"key":"1592_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cncr.24715","volume":"116","author":"JF Shapiro","year":"2010","unstructured":"Shapiro JF, Chase JL, Wolff RA et al (2010) Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 116:316\u2013322","journal-title":"Cancer"},{"key":"1592_CR13","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","volume":"22","author":"JH Choe","year":"2015","unstructured":"Choe JH, Overman MJ, Fournier KF et al (2015) Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 22:2578\u20132584","journal-title":"Ann Surg Oncol"},{"key":"1592_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/crad.2002.0942","volume":"57","author":"TVC Sulkin","year":"2002","unstructured":"Sulkin TVC, O'Neill H, Amin AI et al (2002) CT in Pseudomyxoma Peritonei: A Review of 17 Cases. Clin Radiol 57:608\u2013613","journal-title":"Clin Radiol"},{"key":"1592_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1592_CR16","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE)v4.0. (2010) NCI CTEP. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html."},{"key":"1592_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer\u2013a GERCOR study. J Clin Oncol 24:394\u2013400","journal-title":"J Clin Oncol"},{"key":"1592_CR18","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","volume":"27","author":"B Chibaudel","year":"2009","unstructured":"Chibaudel B, Maindrault-Goebel F, Lledo G et al (2009) Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727\u20135733","journal-title":"J Clin Oncol"},{"key":"1592_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/1097-0142(19920715)70:2<396::AID-CNCR2820700205>3.0.CO;2-A","volume":"70","author":"JW Smith","year":"1992","unstructured":"Smith JW, Kemeny N, Caldwell C et al (1992) Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 70:396\u2013401","journal-title":"Cancer"},{"key":"1592_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1245\/s10434-007-9691-2","volume":"15","author":"D Baratti","year":"2008","unstructured":"Baratti D, Kusamura S, Nonaka D et al (2008) Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 15:526\u2013534","journal-title":"Ann Surg Oncol"},{"key":"1592_CR21","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.clcc.2019.03.002","volume":"18","author":"A Raimondi","year":"2019","unstructured":"Raimondi A, Corallo S, Niger M et al (2019) Metronomic capecitabine with cyclophosphamide regimen in unresectable or relapsed pseudomyxoma peritonei. Clin Colorectal Cancer 18:e179\u2013e190","journal-title":"Clin Colorectal Cancer"},{"key":"1592_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R","volume":"92","author":"BM Ronnett","year":"2001","unstructured":"Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85\u201391","journal-title":"Cancer"},{"key":"1592_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.4161\/cbt.8.15.8943","volume":"8","author":"W-L Sun","year":"2014","unstructured":"Sun W-L, Hutarew G, Gradl J et al (2014) Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther 8:1459\u20131462","journal-title":"Cancer Biol Ther"},{"key":"1592_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2019.00055","volume":"9","author":"W Liu","year":"2019","unstructured":"Liu W, Liu L, Wang R et al (2019) Bevacizumab combined with oxaliplatin\/capecitabine in patient with refractory and recurrent mucinous adenocarcinoma of the appendix: a case report. Front Oncol 9:55","journal-title":"Front Oncol"},{"key":"1592_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000270179","volume":"3","author":"I Winer","year":"2009","unstructured":"Winer I, Buckanovich RJ (2009) Bevacizumab for the treatment of non-resectable pseudomyxoma peritonei associated with mucinous ovarian tumor of low malignant potential\u2014a comparison of two cases. Case Rep Oncol 3:1\u20138","journal-title":"Case Rep Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01592-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T01:55:53Z","timestamp":1607478953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01592-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Chikashi Ishioka received research funding from the Tokyo Cooperative Oncology Group. Chikashi Ishioka received contributions from Chugai Pharmaceutical, Asahi Kasei Pharma Corporation, Ono pharmaceutical, MSD, Pfizer, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceutical, Taiho Pharmaceutical, Eisai Pharmaceutical, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical. Shin Takahashi received lecture fee from Asahi Kasei Pharma Corporation. Masahiro Takahashi has received research funding from Ono Pharmaceutical Company. Masanobu Takahashi has received research funding from Ono Pharmaceutical Company. Chikashi Ishioka is a representative of Tohoku Clinical Oncology Research and Education Society, a specified non-profit corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}